Precigen’s Lead Cancer Therapy Is Fueling A Massive Stock Rally — Here’s What Wall Street Sees Next

• Citizens raised its price target on Precigen to $11 from $9 and kept an ‘Outperform’ rating, according to The Fly.
• H.C. Wainwright noted that Papzimeos sales ‘comfortably exceeded’ guidance.
• Precigen expects to provide updates on PRGN-2009 HPV cancer therapy by the end of the year.

Shares of Precigen Inc (PGEN) soared more than 26% in pre-market trading on Thursday after bullish brokerage calls lifted investor sentiment, driven by a strong performance of the biotech firm’s laryngeal cancer treatment that analysts said “comfortably exceeded” expectations.

If the pre-market levels hold after the opening bell, PGEN shares would climb to more than three-month highs while also clocking their biggest single-day gains in nine months.

Analysts Bullish After PGEN’s Lead Therapy Sales Fly  

Citizens raised its price target on Precigen to $11 from $9 and kept an ‘Outperform’ rating, according to The Fly. This implies a 165% potential upside from Wednesday’s closing price. The brokerage was bullish on Precigen’s strong launch of its lead therapy, Papzimeos, citing the product’s compelling clinical profile and praising the company’s commercial preparation and execution following its market debut.

Meanwhile, H.C. Wainwright raised the price target to $11 from $10 and kept a ‘Buy’ rating following Precigen’s first-quarter report. The firm noted that Papzimeos sales “comfortably exceeded” guidance.

Papzimeos Sales Drive PGEN’s Q1 Beat

Driven by Papzimeos sales, Precigen posted a revenue of $23.3 million, which came in above Wall Street’s estimates of $20.8 million, according to Fiscal.ai data. The company posted a loss of $0.02 per share, compared to the consensus estimates of a loss of $0.04 per share.

“We are pleased with the launch performance of Papzimeos, recognizing $21.6 million of net revenue in the first full quarter of its launch. In the second quarter of 2026, we are seeing continued strength in revenue growth from Papzimeos,” said Harry Thomasian, CFO of Precigen.

The company expects existing cash reserves, along with expected revenue from Papzimeos sales, will be enough to support operations until it reaches cash flow break-even by the end of 2026.

Retail Bullish On PGEN’s HPV Cancer Therapy Candidate

Precigen generated strong buzz among retail traders on Stocktwits, with message volumes surging more than 660% over the past 24 hours. Sentiment also turned ‘extremely bullish’ from ‘bullish’ a day earlier.

Investor sentiment around its HPV cancer therapy candidate, PRGN-2009, remained upbeat, with one user saying the stock could “skyrocket” if the trial delivers successful results.

Another user was bullish about the trial.

PRGN-2009 is an experimental immunotherapy to help the immune system identify and fight HPV-related cancers. The drug is currently being evaluated in Phase 2 clinical trials for HPV-associated throat and cervical cancers. The company expects to provide updates on PRGN-2009 by the end of the year.

The stock has surged nearly 200% over the past year.

For updates and corrections, email newsroom[at]stocktwits[dot]com.